PMI 002
Alternative Names: PMI-002Latest Information Update: 04 Nov 2017
At a glance
- Originator Phytomedics
- Class Antineoplastics; Phytotherapies
- Mechanism of Action Apoptosis stimulants; JNK mitogen-activated protein kinase inhibitors; Multidrug resistance-associated protein 1 inhibitors; P-glycoprotein inhibitors; Phosphotransferase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Aug 2009 Preclinical development is ongoing in USA
- 24 Oct 2003 Preclinical trials in Cancer in USA (unspecified route)